Clinical trial register · China

Clinical Trials in Changsha, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:17 UTC

19224

Studies in scope

all four open statuses

11811

Recruiting now

open to new participants

2030

Lead sponsors

across recruiting studies

Top sites

Beijing 5586 Shanghai 3885 Guangzhou 3356 Hangzhou 1825 Wuhan 1342

Trials with a site in Changsha

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Beijing, Chongqing, Guangzhou, Guiyang, Harbin, Wuhan, Changsha, Nanjing

2027-11-23

Not yet open

Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support

NCT07751003COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation of COPD, Hypercapnia

Sir Run Run Shaw Hospital

Not applicable

236

Zhengzhou, Changsha, Hangzhou, Wenling

2027-08-01

Not yet open

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

NCT07915219Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,500

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei

2027-01-11

Not yet open

Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications

NCT07444463Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD)

Central South University

Not applicable

400

Changsha

2027-01-01

Not yet open

Unplanned Hospitalization and Emergency Department Use in Patients With Head and Neck Cancer Receiving Radiotherapy

NCT07929194Head and Neck Neoplasms

Xiangya Hospital of Central South University

Observational

657

Changsha

2026-12-01

Not yet open

Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG

NCT07918781Postoperative Atrial Fibrillation, Coronary Artery Disease

China National Center for Cardiovascular Diseases

Not applicable

1,470

Beijing, Guangzhou, Zhenzhou, Changsha, Nanjing

2026-12-01

Not yet open

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

NCT07881432Obesity

DrugsEloralintide and tirzepatide·Eloralintide·Tirzepatide

Eli Lilly and Company

Phase 3

2,115

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan

2026-12

Not yet open

A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes

NCT07918625Overweight or Obese Participants Without Diabetes

BrightGene Bio-Medical Technology Co., Ltd.

Phase 2

160

Changsha

2026-11-30

Not yet open

Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project)

NCT07885904Type 2 Diabetes Mellitus

Xiangya Hospital of Central South University

Not applicable

15,400

Changsha

2026-11-30

Not yet open

A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants

NCT07922798Overweight , Obesity

The United Bio-Technology (Hengqin) Co., Ltd.

Phase 1

Changsha

2026-11-29

Not yet open

Health Information Framing, Source Characteristics, and Health Behavior Promotion

NCT07927387Vaccination, Mental Health, Health Behavior, Health Communication

Peking University

Not applicable

102,000

Beijing, Changsha

2026-11-28

Not yet open

A Study to Evaluate the PK/PD and Safety of KL0011034 Injection in Healthy Non-Elderly and Elderly Trial Participants

NCT07913048Healthy Participants

DrugKL0011034

Hunan Kelun Pharmaceutical Co., Ltd.

Phase 1

Changsha

2026-11-20

Not yet open

Phase I Trial of HHK101 in Patients With Schizophrenia

NCT07815210Schizophrenia

Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.

Phase 1

Changsha, Xi'an, Shanghai, Huzhou

2026-11-15

Recruiting

The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain

NCT07795554Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain

Second Xiangya Hospital of Central South University

Not applicable

Changsha

2026-11-01

Not yet open

Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07912268ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsRosuvastatin Calcium·Repaglinide·Fexofenadine·Bupropion

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

270

Fuzhou, Harbin, Changsha, Nanchang, Changchun, Shanghai, Taizhou

2026-11-01

Not yet open

Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study

NCT07878871Lung Adenocarcinoma, Stage III Lung Cancer, EGFR Positive Non-small Cell Lung Cancer

DrugFurmonertinib

Hunan Province Tumor Hospital

Phase 2

Changsha

2026-11

Not yet open

A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants

NCT07906691Pancreatic Cancer

DrugItraconazole

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1

Changsha

2026-11

Not yet open

A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis

NCT07909655Idiopathic Pulmonary Fibrosis (IPF)

DrugHB0056

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 2

Changsha, Shanghai

2026-11

Not yet open

Temporal Interference Stimulation Targeting Thalamus for Schizophrenia-Related Cognitive Dysfunction

NCT07927790Schizophrenia Disorder, Cognitive Impairments

Central South University

Not applicable

Changsha

2026-11

Recruiting

Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis

NCT07755956Endometriosis

DrugEnantone

Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.

Phase 1

Changsha, Suzhou

2026-10-31

Not yet open

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

NCT07222553Immunoglobulin G4-related Disease

DrugInebilizumab

Amgen

Phase 2

Beijing, Changsha

2026-10-31

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Beijing, Chongqing, Guangzhou, Shijiazhuang, Luoyang, Changsha, Changzhou, Nanjing

2026-10-26

Recruiting

tACS for Working Memory in Schizophrenia

NCT07701343Schizophrenia, Working Memory

Central South University

Not applicable

Changsha

2026-10-26

Not yet open

Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder

NCT07909200Generalized Anxiety Disorder (GAD)

Central South University

Not applicable

Fuzhou, Changsha, Yangzhou

2026-10-25

Not yet open

Clinical Trial of SEEG for Drug-resistant Epilepsy

NCT07923058Drug-Resistant Epilepsy

Beijing Pins Medical Co., Ltd

Not applicable

Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Wuhan, Changsha, Jinan

2026-10-23

Not yet open

Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer

NCT07882628Pulmonary Nodules, Early Detection of Cancer, Lung Neoplasms

Beijing Chao Yang Hospital

Observational

1,050

Beijing, Changsha

2026-10-21

Not yet open

hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease

NCT07471698Ischemic Heart Failure, CABG-patients

HELP Therapeutics Co., Ltd.

Phase 1/2

Changsha

2026-10-20

By invitation

A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

NCT07847905Advanced Solid Tumor Cancer

DrugsLM-364·Tislelizumab

LaNova Medicines Limited

Phase 1/2

Beijing, Xinxiang, Shiyan, Changsha, Liaocheng, Shanghai, Wenzhou

2026-10-20

Not yet open

TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread

NCT07844187Colorectal Neoplasms

DrugsCalcium folinate·Fluorouracil·Oxaliplatin

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 1/2

Beijing, Lanzhou, Foshan, Nanning, Harbin, Zhengzhou, Wuhan, Changsha

2026-10-20

Recruiting

Study of UBT37034 Injection

NCT07873645Overweight , Obesity

The United Bio-Technology (Hengqin) Co., Ltd.

Phase 1

Changsha

2026-10-15

Recruiting

A Study of DS-3939a in Participants With Solid Tumors

NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsDS-1103a·DS-3939a·Pemetrexed·Carboplatin

Daiichi Sankyo

Phase 1/2

400

Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Hexi District, Tianjin, Jiamusi

2026-10-13

Not yet open

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult Subjects

NCT07828470Healthy Volunteers

DrugsKL0011034·Propofol

Hunan Kelun Pharmaceutical Co., Ltd.

Phase 1

Changsha

2026-10-13

By invitation

A Clinical Trial Evaluating the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty in China

NCT07872826Pain After Abdominal Surgery

DrugRopivacaine hydrochloride

The Third Xiangya Hospital of Central South University

Phase 3

300

Changsha

2026-10-10

Not yet open

Online Tai Chi Versus Digital CBT-I for Chronic Insomnia

NCT07853651Chronic Insomnia Disorder

The Third Xiangya Hospital of Central South University

Not applicable

172

Changsha

2026-10-10

Recruiting

A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.

NCT07877818Gastric, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

140

Beijing, Bengbu, Changchun, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou

2026-10-09

Recruiting

A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia

NCT07805980Schizophrenia, Antipsychotic Induced Weight Gain

Second Xiangya Hospital of Central South University

Not applicable

Changsha

2026-10-01

Not yet open

A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)

NCT07832201Influenza

DrugVaxigrip

Sinovac Biotech Co., Ltd

Phase 4

150

Changsha, Chengdu, Chongqing, Guangzhou, Nanjing, Wuhan

2026-10

Not yet open

Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients

NCT07869797Cancer Pain

Mundipharma (China) Pharmaceutical Co. Ltd

Observational

378

Beijing, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2026-10

Recruiting

Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma

NCT07796789Nasopharyngeal Cancinoma (NPC)

DrugNanocrystalline Megestrol Acetate

Sun Yat-sen University

Phase 3

204

Guangzhou, Changsha, Fuzhou

2026-09-29

Recruiting

Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN)

NCT07888517Neurofibromatosis Type 1 (NF1)

AstraZeneca

Observational

800

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang

2026-09-28

Recruiting

A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials

NCT07894341Idiopathic Short Stature

DrugInpegsomatropin

Xiamen Amoytop Biotech Co., Ltd.

Not applicable

300

Beijing, Changsha, Chengdu, Guangzhou, Hefei, Jiaxing, Jining, Kunming

2026-09-26

Recruiting

Clarify HPP: Disease Burden of HPP Patients in China

NCT07905287Hypophosphatasia (HPP)

AstraZeneca

Observational

200

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Huai'an

2026-09-26

Recruiting

HMPL-A830 in Solid Tumors

NCT07718581Solid Tumor, Adult

Hutchmed

Phase 1/2

147

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Jinan, Nanjing, Taiyuan

2026-09-24

Recruiting

AXT-1003 Combination With Enzalutamide in Participants With mCRPC

NCT07897071mCRPC

Axter Therapeutics (Beijing) Co., Ltd

Phase 1

105

Guangzhou, Changsha, Shanghai, Ningbo

2026-09-24

Recruiting

A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors

NCT07763639Head and Neck Tumors, Solid Tumors

DrugSI-B036

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Changsha, Shanghai

2026-09-23

Recruiting

Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)

NCT07767253Dermatitis, Atopic

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 3

246

Beijing, Guangzhou, Changsha, Hangzhou

2026-09-22

Not yet open

An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors

NCT07774611Advanced Solid Tumors

DrugBevacizumab

Hangzhou Sumgen Biotech Co., Ltd.

Phase 1/2

180

Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun

2026-09-22

Recruiting

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants

NCT07802964Psoriasis Vulgaris

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 1

Changsha

2026-09-21

Recruiting

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

NCT07867080Diabetic Macular Edema (DME)

Drug4D-150 IVT

4D Molecular Therapeutics

Phase 3

514

Beijing, Changchun, Changsha, Haerbin, Hangzhou, Jinan, Lanzhou, Nanchang

2026-09-18

Recruiting

A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.

NCT07686120Uncontrolled Hypertension

DrugBaxdrostat

AstraZeneca

Phase 3

286

Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou

2026-09-17

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou

2026-09-17

Recruiting

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

NCT07851025Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·Avastin·Bevacizumab

AstraZeneca

Phase 3

950

Anyang, Beijing, Binzhou Shi, Changchun, Changsha, Chengdu, Chongqing, Fuzhou

2026-09-16

Recruiting

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DrugsSaruparib·Abiraterone·Darolutamide·Enzalutamide

AstraZeneca

Phase 3

1,330

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jiaxing

2026-09-15

Recruiting

Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects

NCT07697443Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2

300

Guangzhou, Meizhou, Wuhan, Changsha, Chengdu, Tianjin

2026-09-12

Recruiting

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

NCT07659574Type 2 Diabetes

DrugUBT251

The United Bio-Technology (Hengqin) Co., Ltd.

Phase 3

360

Changsha

2026-09-07

By invitation

Efficacy and Safety of HRS-9190 in General Anesthesia

NCT07733245Adult Participants Requiring Tracheal Intubation Under General Anesthesia for Elective Surgery

The Third Xiangya Hospital of Central South University

Phase 3

320

Changsha

2026-09-02

Recruiting

Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults

NCT07746726Neuromuscular Blockade

DrugRocuronium

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

320

Changsha, Wenzhou

2026-09-02

Not yet open

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

NCT07760155Systemic Lupus Erythematosus (SLE)

DrugESG206

Shanghai Escugen Biotechnology Co., Ltd

Phase 2

Shenzhen, Zhongshan, Guilin, Liupanshui, Handan, Shijiazhuang, Changde, Changsha

2026-09-01

Not yet open

Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL

NCT07831395Richter Syndrome

DrugsLiposomal mitoxantrone·Lisaftoclax·Pirtobrutinib·Rituximab

Institute of Hematology & Blood Diseases Hospital, China

Phase 2

Zhengzhou, Changsha, Nanchang, Guangzhou, Nanjing, Wuhan

2026-09-01

Not yet open

Study of SG301 for Renal AMR After Transplantation

NCT07764627Antibody Mediated Rejection

DrugSG301

Hangzhou Sumgen Biotech Co., Ltd.

Phase 2

Guangzhou, Nanning, Zhengzhou, Changsha, Jinan, Chengdu, Hangzhou

2026-09-01

Recruiting

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

NCT07624305Renal Insufficiency, Chronic

DrugDapagliflozin

AstraZeneca

Phase 3

2,800

Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan

2026-09-01

Not yet open

A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure

NCT07783815Bladder Cancer

DrugToripalimab

Xiangya Hospital of Central South University

Phase 1

Changsha

2026-09-01

Not yet open

Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature

NCT07815626Idiopathic Short Stature (ISS)

DrugHuman Growth Hormone

Zhongshan Sansure Hygene Biomedicine Co., Ltd.

Phase 3

240

Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing

2026-09

Not yet open

Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

NCT07712588Diffuse Large B-Cell Lymphoma (DLBCL)

DrugsBirelentinib·Cyclophosphamid·Vincristine·Doxorubicin

Dizal Pharmaceuticals

Phase 2/3

880

Chongqing, Harbin, Changsha, Jinan, Shanghai

2026-09

Not yet open

Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

NCT07691515Intrahepatic Cholangiocarcinoma (Icc)

DrugsLenvatinib·Tislelizumab·Gemcitabine·Cisplatin

Zhejiang Cancer Hospital

Phase 3

140

Guangzhou, Jiangmen, Wuhan, Changsha, Ganzhou, Jinan, Qingdao, Chengdu

2026-09

Not yet open

A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

NCT07833098Hypertension, Resistant Hypertension, Uncontrolled Hypertension

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

Phase 2

240

Baotou, Beijing, Changsha, Chengdu, Chongqing, Daqing, Hebei, Hengyang

2026-09

Recruiting

A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

NCT07751848Lupus Erythematosus, Systemic

DrugAnifrolumab

AstraZeneca

Phase 3

417

Beijing, Bengbu, Changchun, Changde, Changlexi, Changsha, Chengdu, Dalian

2026-08-31

Recruiting

A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis

NCT07622342Generalized Myasthenia Gravis

DrugSHR-2173

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 2

Changsha, Shanghai

2026-08-28

Recruiting

Artificial Intelligence Support for Stroke

NCT07785492Ischemic Stroke, Acute

Capital Medical University

Not applicable

516

Changsha

2026-08-26

Recruiting

To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.

NCT07760467Paroxysmal Nocturnal Hemoglobinuria, PNH

Zhuhai United Laboratories Co., Ltd.

Phase 1

Changsha

2026-08-26

Recruiting

A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07779252Moderate to Severe Glabellar Lines

DrugCorabotase

Ipsen

Phase 3

160

Guangzhou, Changsha, Nanjing, Wuxi, Jing’an, Chengdu, Hangzhou, Beijing

2026-08-25

Recruiting

A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors

NCT07730190Advanced Malignancies

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 1

145

Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai

2026-08-25

Recruiting

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

NCT07747857Type 2 Diabetes Mellitus Combined With Overweight or Obesity

DrugTQF3250

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1

Fuzhou, Guangzhou, Langfang, Luoyang, Wuhan, Yichang, Changsha, Nanjing

2026-08-25

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Baoding, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu

2026-08-24

Not yet open

VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors

NCT07772934Advanced Solid Tumors

VelaVigo Bio Inc

Phase 1/2

260

Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan

2026-08-24

Recruiting

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

NCT07775404Obesity, Overweight

DrugElecoglipron

AstraZeneca

Phase 3

351

Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi

2026-08-21

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing

2026-08-21

Recruiting

A Study of HW243040 in Healthy Participants

NCT07737496Healthy

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Phase 1

Changsha

2026-08-20

Not yet open

Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome

NCT07765914Nephrotic Syndrome

DrugsPrednisolone/prednisone·Zuberitamab

Children's Hospital of Fudan University

Phase 3

120

Shanghai, Changsha, Guiyang, Wuhan, Wuxi, Xiamen

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725Obesity or Overweight

DrugLenbelintide

AstraZeneca

Phase 3

2,500

Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang

2026-08-19

Not yet open

Couple-Coordinated Lifestyle Intervention for Women With a History of Gestational Diabetes Mellitus

NCT07762625Diabetes Prevention, GDM, Lifestyle Intervention, Couples

The Third Xiangya Hospital of Central South University

Not applicable

362

Changde, Changsha, Huaihua

2026-08-15

Not yet open

Clinical Study of Zuogui Jiangtang Shuluo Formula in Treating Diabetic Peripheral Neuropathy

NCT07771894Diabetic Peripheral Neuropathy (DPN)

DrugMecobalamin

The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Not applicable

Changsha

2026-08-15

Recruiting

Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

NCT07251582Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

Hunan Province Tumor Hospital

Phase 3

186

Changsha

2026-08-12

Recruiting

SMP-656 for HER2-Positive Advanced Breast Cancer

NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)

Chengdu SciMount Pharmatech Co., Ltd.

Phase 2

Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing

2026-08-10

Not yet open

Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

NCT07741045Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset

DrugTJ0113

Hangzhou PhecdaMed Co., Ltd.

Phase 3

300

Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai

2026-08-03

Not yet open

EEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes

NCT07760415Sepsis, Sepsis Associated Encephalopathy, Sepsis and Septic Shock, Sepsis at Intensive Care Unit

Xiangya Hospital of Central South University

Observational

Changsha

2026-08-01

Recruiting

Community Dining, Walking, and Glucose in Older Adults

NCT07695675Prediabetes

Yang Zhang

Not applicable

Changsha

2026-08-01

Not yet open

Comparison of Liposomal Bupivacaine Paravertebral Nerve Block Versus Intercostal Nerve Block on Postoperative Glycemic Variability in Patients Undergoing Minimally Invasive Pulmonary Resection: A Randomized Controlled Non-Inferiority Trial

NCT07754916Thoracic Surgery, Glycemic Variability

Xiangya Hospital of Central South University

Not applicable

Changsha

2026-08-01

Not yet open

Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer

NCT07780877Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma

Fudan University

Phase 2

Changsha, Shanghai

2026-08

Not yet open

A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis

NCT07758075Plaque Psoriasis

DrugSHR-1139

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 2

Changsha

2026-08

Not yet open

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy

NCT07765537Primary Membranous Nephropathy

DrugFKC289

Shenzhen Fosun Kairos Biotechnology Co., Ltd.

Phase 1/2

Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu

2026-08

Not yet open

A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome

NCT07727486Primary Sjögren's Syndrome

DrugICP-488

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2

240

Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Changsha, Zhuzhou

2026-08

Not yet open

Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT07721012Patients With Irritable Bowel Syndrome With Diarrhea

Lei Yunshang Group

Phase 2

120

Beijing, Changsha, Daqing, Guangzhou, Hohhot, Lianyungang, Luoyang, Meihekou

2026-07-31

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang

2026-07-27

Recruiting

Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma

NCT07661771Non-metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3

568

Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan, Changsha

2026-07-24

Recruiting

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

NCT07366034Fibrosing Interstitial Lung Disease

DrugNerandomilast

Boehringer Ingelheim

Phase 3

Beijing, Changsha, Shanghai

2026-07-21

Active, closed

Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets

NCT07608666Myelofibrosis

DrugRovadicitinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1

Changsha

2026-07-20

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsRilvegostomig·Enfortumab Vedotin·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou

2026-07-16

Recruiting

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

NCT07640295Metastatic Pancreatic Ductal Adenocarcinoma

Jacobio Pharmaceuticals Co., Ltd.

Phase 1/2

Beijing, Hangzhou, Changsha, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan

2026-07-16

Recruiting

Digital Mindfulness-Based Therapy for Obsessive-Compulsive Disorder

NCT07701616Obsessive-Compulsive Disorder

Central South University

Not applicable

150

Changsha

2026-07-15

Recruiting

A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

NCT07557446Osteogenesis Imperfecta (OI)

DrugAGA2115

Angitia Biopharmaceuticals Guangzhou Limited

Phase 2

Beijing, Shenzhen, Changsha, Suzhou, Shanghai

2026-07-14

Not yet open

A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

NCT07677514Crohn's Disease

Jiangsu Carephar Pharmaceutical Co., Ltd.

Phase 2

156

Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou

2026-07-12

Recruiting

Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors

NCT07692841Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor

DrugG-Csf

First Affiliated Hospital of Zhejiang University

Phase 3

560

Changsha, Hangzhou, Jinhua, Ningbo, Wenzhou

2026-07-10

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2026-07-10

Not yet open

Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed

NCT07674368ALK Fusion-positive Non-small Cell Lung Cancer

DrugRecaticimab

Hunan Cancer Hospital

Phase 4

Changsha

2026-07-10

Recruiting

Safety and Efficacy of Eculizumab in High-risk TA-TMA

NCT07707687Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

DrugEculizumab

First Affiliated Hospital of Zhejiang University

Phase 2

Changsha, Hangzhou, Jinhua, Ningbo, Wenzhou

2026-07-10

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553Type 2 Diabetes Mellitus

DrugElecoglipron

AstraZeneca

Phase 3

600

Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang

2026-07-08

Recruiting

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

NCT07662213Type 2 Diabetes Mellitus

DrugsElecoglipron·Semaglutide

AstraZeneca

Phase 3

1,200

Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang

2026-07-06

Recruiting

Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

NCT07586124Head and Neck Squamous Cell Carcinoma

DrugsPucotenlimab·Becotatug Vedotin

Lepu Biopharma Co., Ltd.

Phase 2

Beijing, Fuzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changsha

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

2,000

Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

900

Binzhou, Changsha, Chengdu, Hangzhou, Jinan, Liaocheng, Liuzhou, Luoyang

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

800

Baotou, Binzhou, Cangzhou, Changsha, Chengdu, Ganzhou, Haikou, Hangzhou

2026-07-06

Recruiting

The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

NCT07614152Turner Syndrome

DrugInpegsomatropin

Xiamen Amoytop Biotech Co., Ltd.

Phase 3

Anyang, Beijing, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou

2026-07-05

Recruiting

A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07660432Neoplasms, Malignant

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

472

Fuzhou, Zhengzhou, Changsha, Shenyang, Jinan, Hangzhou

2026-07-03

Not yet open

Zishen Yutai Pill for Patients With Recurrent Implantation Failure

NCT07641088Recurrent Implantation Failure

Peking University Third Hospital

Not applicable

878

Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Nanjing, Xi'an

2026-07-01

Not yet open

Infrared Fluorescence Staining Versus Frozen Section for Prostate Cancer Surgery

NCT07690462Prostate Cancer

Xiangya Hospital of Central South University

Observational

120

Changsha

2026-07

Recruiting

Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)

NCT07719140Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)

DrugPrednisone

Peking Union Medical College Hospital

Phase 4

198

Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Changchun, Shanghai

2026-07

Not yet open

Brain Functional Connectivity Mechanism of Cognitive Flexibility Impairment and rTMS Intervention in Major Depressive Disorder

NCT07161492Depressive Disorder, Major, Cognitive Impairment

Second Xiangya Hospital of Central South University

Not applicable

105

Changsha

2026-07

Recruiting

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07564596Systemic Lupus Erthematosus

DrugBudoprutug

Climb Bio, Inc.

Phase 1/2

Mianyang, Baoji, Beijing, Bengbu, Changsha, Hefei, Nanchang, Suzhou

2026-06-30

Recruiting

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

NCT07604766Platinum-resistant Ovarian Cancer

DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine

Genmab

Phase 3

Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan

2026-06-26

Recruiting

A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07774403Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot

2026-06-24

Recruiting

TIS for Improving Cognitive Impairment in Schizophrenia

NCT07647380Schizophrenia Disorder, Cognitive Impairments

Central South University

Not applicable

Changsha

2026-06-24

Recruiting

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

NCT07314216NSCLC (Non-small Cell Lung Carcinoma), Stage III, EGFR Uncommon Mutations

DrugFurmonertinib

Hunan Cancer Hospital

Phase 2

Changsha

2026-06-22

Recruiting

Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities

NCT07781124End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)

Vantive Health LLC

Observational

750

Beijing, Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha

2026-06-17

Recruiting

N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

NCT07639450Advanced Malignant Solid Tumors

DrugPembrolizumab

Hefei Xinzhu Biological Technology Co., Ltd.

Phase 1/2

114

Changsha, Shanghai, Zhengzhou

2026-06-15

Active, closed

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugsCliramitug·Eplontersen

AstraZeneca

Phase 2

326

Beijing, Changsha, Chongqing, Guangzhou, Hangzhou

2026-06-11

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing

2026-06-11

Recruiting

Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis

NCT07516184Suspected Asthma

AstraZeneca

Not applicable

500

Beijing, Cangzhou, Changsha, Chengdu, Chongqing, Guangzhou, Kunming, Quanzhou

2026-06-10

Not yet open

Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0

NCT07682415CLL / SLL

DrugSonrotoclax

Yi Shuhua

Phase 2

Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin

2026-06-08

Active, closed

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation

DrugsTNO155·Opnurasib·Trametinib·Cetuximab

Novartis Pharmaceuticals

Phase 1/2

Guangzhou, Changsha

2026-06-08

Not yet open

AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents

NCT07593170Obesity, Obese Adolescents, Obese Children and Adolescents, Akkermansia Muciniphila

Central South University

Phase 2

100

Changsha

2026-06-06

Not yet open

Impact of Radiotherapy-Immunotherapy Timing in NSCLC Brain Metastases

NCT07638709Non Small Cell Lung, Brain Metastasases

Xiangya Hospital of Central South University

Observational

150

Changsha

2026-06-05

Recruiting

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT07544056Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer

DrugsBEBT-209·Gemcitabine·Carboplatin

BeBetter Med Inc

Phase 2/3

446

Guangzhou, Changsha

2026-06-04

Not yet open

Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia

NCT07652866Schizophrenia Disorder

Second Xiangya Hospital of Central South University

Not applicable

Changsha

2026-06-02

Recruiting

Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma

NCT07652489Adenoid Cystic Carcinoma, Sinonasal Carcinoma

Eye & ENT Hospital of Fudan University

Observational

Harbin, Changsha, Shenyang, Shanghai, Xi’an, Wenzhou

2026-06-01

Not yet open

Transcranial Alternating Current Stimulation to Enhance Mindfulness Therapy in Generalized Anxiety Disorder

NCT07648797Generalized Anxiety Disorder (GAD)

Central South University

Not applicable

Changsha

2026-06-01

Recruiting

Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer

NCT07886229Resectable Non-Small-Cell Lung Cancer

DrugsPropranolol·JS001·Toripalimab

Second Xiangya Hospital of Central South University

Phase 1

Changsha

2026-06-01

Not yet open

Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research

NCT07611695Pulmonary Tuberculosis, Tuberculosis (TB), Tuberculosis Active

Huashan Hospital

Observational

31,600

Changsha, Shanghai

2026-06-01

Not yet open

Effect of Biologic vs Synthetic Mesh on Chronic Pain After Laparoscopic Repair of Contralateral Asymptomatic Hernia in Patients With Unilateral Symptomatic Inguinal Hernia

NCT07649434Hernia Inguinal, Biologic Mesh

Xiangya Hospital of Central South University

Not applicable

Changsha

2026-06

Not yet open

Treatment of Recurrent/Metastatic Head and Neck Cancer

NCT07601204Recurrent/Metastatic Head and Neck Cancer

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 1/2

128

Beijing, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Taiyuan, Chengdu

2026-06

Not yet open

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy Volunteers

NCT07618156Healthy Volunteers (HV)

Jiangxi Kvvit Pharmaceutical Co., Ltd.

Phase 1

Changsha

2026-06

Not yet open

Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

NCT07627464Renal Cell Carcinoma (RCC)

DrugsAnlotinib hydrochloride·Benmelstobart

Tianjin Medical University Cancer Institute and Hospital

Phase 2

144

Beijing, Changchun, Changsha, Hangzhou, Kunming, Nanjing, Nanning, Qingdao

2026-05-31

Not yet open

JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

NCT07582822Advanced Solid Tumor

Biotech Pharmaceutical Co., Ltd.

Phase 1

Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu

2026-05-30

Recruiting

Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer

NCT07886047Small Cell Lung Cancer (SCLC)

DrugsPropranolol·Adebrelimab

Second Xiangya Hospital of Central South University

Phase 1

Changsha

2026-05-29

Not yet open

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations

NCT07414290Parkinson Disease (PD)

Shanghai Vitalgen BioPharma Co., Ltd.

Phase 1/2

Changsha

2026-05-25

Recruiting

Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia

NCT07591298Diagnosed With HoFH

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 2

Changsha

2026-05-24

Recruiting

Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative Pain

NCT07491146Pain After Abdominal Surgery

DrugsHSK55718·Morphine

Yingyong Zhou,MD,PhD

Phase 2

200

Changsha, Chengdu

2026-05-23

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843Crohn Disease

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

460

Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou

2026-05-22

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery

NCT07533786Pain After Surgery

DrugsHSK55718·Morphine

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

200

Changsha, Chengdu

2026-05-22

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Nanjing, Shanghai, Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou

2026-05-21

Recruiting

Study on iTBS Regulating the Reward Circuit Function to Improve Anhedonia in Depression

NCT07813169Major Depression, Anhedonia, Melancholic Depression, Theta Burst Stimulation

Guo Wenbin

Not applicable

Changsha

2026-05-19

Recruiting

Adaptive DBS for PD

NCT07635823Parkinson Disease(PD)

Beijing Pins Medical Co., Ltd

Not applicable

Hefei, Beijing, Guangzhou, Changsha, Nanjing, Jinan, Chengdu

2026-05-16

Not yet open

A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)

NCT07593144Advanced Solid Tumors

Foresight Therapeutics (Hefei) Co., Ltd.

Phase 1

156

Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun

2026-05-15

Not yet open

Effects of Cofrogliptin on Beta-Cell Function in LADA Patients

NCT07460336Latent Autoimmune Diabetes in Adults (LADA)

DrugsCofrogliptin·Cholecalciferol·Metformin

Second Xiangya Hospital of Central South University

Not applicable

Changsha

2026-05-15

Not yet open

Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC

NCT07643350NSCLC

DrugBenmelstobart

The Third Xiangya Hospital of Central South University

Phase 2

152

Changsha

2026-05-15

Active, closed

A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.

NCT07565597Healthy

DrugsGecacitinib Hydrochloride·Gecacitinib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1

Changsha

2026-05-12

Active, closed

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Beijing, Lanzhou, Foshan, Guangzhou, Harbin, Changsha, Baotou, Nanjing

2026-05-11

Recruiting

Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer

NCT07529626Pancreatic Tumor, Benign, Pancreatic Cancer, Adult, Pancreatic Cancer Resectable

Shanghai Zhongshan Hospital

Observational

320

Changsha, Shanghai, Xi’an

2026-05-11

Recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001Obesity, Heart Failure

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

5,610

Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou

2026-05-11

Recruiting

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

NCT07608003Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme, Glioma of Brainstem, Glioma, Diffuse Midline, H3K27M-mutant

Xiangya Hospital of Central South University

Observational

500

Changsha

2026-05-10

Not yet open

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

NCT06706219Non Small Cell Lung Cancer (Stage III)

DrugsSacituzumab tirumotecan·Toripalimab

Hunan Province Tumor Hospital

Phase 2

Changsha

2026-05-10

Recruiting

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery

NCT07699601Postoperative Pain

DrugsOxycodone-Acetaminophen·HL-1186

Shanghai Huilun Pharmaceutical Co., Ltd.

Phase 2/3

330

Changsha

2026-05-09

Recruiting

A Clinical Study of Cizutamig in Thyroid Eye Disease

NCT07597200Thyroid Eye Disease, TED

Candid Therapeutics

Phase 1

Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Changsha, Wuhan, Nanchang

2026-05-08

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031Solid Tumors

DrugsAdagrasib·Fluorouracil·Leucovorin·Irinotecan

Mirati Therapeutics Inc.

Phase 2

170

Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan

2026-05-06

Recruiting

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen

2026-05-04

Recruiting

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073Colitis, Ulcerative, Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen

2026-05-04

By invitation

Precision Antithrombotic Therapy

NCT07654634Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke

The Third Xiangya Hospital of Central South University

Observational

5,000

Changsha

2026-05-01

Not yet open

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

NCT07001995Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC

DrugsEtoposide and carboplatin·Limertinib

Hunan Province Tumor Hospital

Phase 2

Changsha

2026-05-01

Not yet open

Prospective International Multi-center Clinical Trial of PGT-A Upgrade

NCT07533630Infertility Assisted Reproductive Technology

Reproductive & Genetic Hospital of CITIC-Xiangya

Observational

1,700

Changsha, Nanjing, Kunming

2026-05

Recruiting

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

NCT07571161Alzheimer Disease

DrugDonanemab

Eli Lilly and Company

Phase 3

140

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei

2026-04-30

Not yet open

A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus

NCT07557927Discoid Lupus Erythematosus

DrugsDihydroartemisinin·Hydroxychloroquine

Kunming Pharmaceuticals, Inc.

Phase 2

100

Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shenyang, Kunming, Hangzhou

2026-04-30

Recruiting

A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

NCT07338487Locally Advanced Cervical Cancer, Cachexia

DrugNanocrystalline Megestrol Acetate

Second Xiangya Hospital of Central South University

Phase 1

Changsha

2026-04-30

Recruiting

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

NCT07474727Colorectal Cancer

DrugsAMT-676·Leucovorin·Irinotecan·Cetuximab

Multitude Therapeutics Inc.

Phase 2

180

Fuzhou, Nanning, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Shengyang

2026-04-29

Recruiting

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors

NCT07537881Solid Tumors

RemeGen Co., Ltd.

Phase 1/2

326

Hunan, Sichuan, Fujian, Guangdong, Guizhou, Heilongjiang, Changsha, Nanjing

2026-04-27

Recruiting

A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

NCT07520162Chronic Rhinosinusitis With Nasal Polyps

DrugTezepelumab

AstraZeneca

Phase 3

230

Beijing, Bengbu, Cangzhou, Changsha, Chengdu, Chongqing, Foshan, Fuzhou

2026-04-24

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang

2026-04-23

Recruiting

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT07365995Metastatic Castration-resistant Prostate Cancer

DrugsBNT324·Prednisone/Prednisolone·Docetaxel

BioNTech SE

Phase 3

736

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Hefei, Nanchang

2026-04-22

Active, closed

Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

NCT07338942ATTR-CM

AstraZeneca

Not applicable

4,000

Beijing, Changlexi, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangdong Province

2026-04-21

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181Systemic Lupus Erythematosus

DrugBI 3000202

Boehringer Ingelheim

Phase 2

405

Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai

2026-04-20

Not yet open

Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes

NCT07558525Prediabetes

Second Xiangya Hospital of Central South University

Not applicable

472

Quanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changde, Changsha, Loudi

2026-04-18

Recruiting

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC

NCT07235319Nasopharangeal Cancer, Distant Metastasis

Sun Yat-sen University

Phase 3

260

Guangzhou, Changsha, Fuzhou, Hangzhou, Nanning

2026-04-16

Recruiting

Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery

NCT07525986Laparoscopic Surgery, Visceral Pain, Postoperative, Anrikefon, Patient-controlled Intravenous Analgesia

DrugsAnrikefon·Morphine

Peking University First Hospital

Phase 4

140

Beijing, Shenzhen, Changsha

2026-04-14

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin

2026-04-13

Recruiting

SAVE-PCI Ⅱ: NyokAssist™ Small-Bore VAD vs. ECMO in Elective High-Risk PCI

NCT07860671High-risk PCI

magAssist, Inc.

Not applicable

204

Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Shenyang, Suzhou, Xi'an

2026-04-09

Recruiting

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

NCT07390123IgA Nephropathy (IgAN)

DrugHSK39297

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

370

Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai

2026-04-07

Active, closed

RET-Targeted Molecular Imaging Probes in Prostate Cancer

NCT07886138Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer

Xiangya Hospital of Central South University

Early Phase 1

Changsha

2026-04-03

Recruiting

A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection

NCT07489482Diabetes Mellitus

DrugSHR-3167

Jiangsu HengRui Medicine Co., Ltd.

Phase 1

Changsha

2026-04-02

Recruiting

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

NCT07548177Alveolar Soft Part Sarcoma

DrugsAnlotinib hydrochloride·Benmelstobart

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun

2026-04-02

Recruiting

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

NCT07295821Lung Cancer

DrugOsimertinib

AstraZeneca

Phase 2

Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin

2026-04-01

Recruiting

Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)

NCT07907341Pheochromocytoma and Paraganglioma (PPGL)

DrugBelzutifan

Longfei Liu，MD

Phase 4

Changsha

2026-04-01

Recruiting

Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.

NCT07519109Postoperative Pain

DrugRopivacaine hydrochloride

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 1

Changsha

2026-03-30

Recruiting

Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery

NCT07383909Aortic Dissection Type A

Fujian Medical University

Not applicable

1,312

Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian

2026-03-29

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 3

770

Fuzhou, Guangzhou, Wuhan, Changsha, Chengdu, Hangzhou, Beijing, Shanghai

2026-03-24

Not yet open

Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites

NCT07475715Allergic Rhinitis Due to Dust Mite

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Phase 2

250

Hefei, Nanning, Haikou, Jingzhou, Wuhan, Changsha, Hengyang, Nanchang

2026-03-23

Recruiting

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

NCT07293260Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

406

Beijing, Zhengzhou, Changsha, Nanjing, Yinchuan, Xi'an, Jinan

2026-03-23

Recruiting

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT07409428Relapsed/Refractory Diffuse Large B-Cell Lymphoma

DrugsR-GemOx·Rituximab·Oxaliplatin

Hutchmed

Phase 3

240

Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing

2026-03-20

Recruiting

A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases

NCT07412691Skin Diseases

BeOne Medicines

Phase 1

Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai

2026-03-19

Active, closed

A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients

NCT07446738Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Observational

146

Guangzhou, Shenyang, Jinan, Changchun, Changsha, Chengdu, Haikou, Kunming

2026-03-19

Recruiting

A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy

NCT07777861Primary Open-Angle Glaucoma, Optic Nerve Injury

Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.

Phase 2

Beijing, Guangzhou, Shantou, Changsha, Tianjin, Hangzhou, Wenzhou

2026-03-18

Recruiting

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Calderasib

Merck Sharp & Dohme LLC

Phase 3

400

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha

2026-03-18

Recruiting

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

NCT07498478Breast Cancer

DrugsTinengotinib·Fulvestrant

TransThera Sciences (Nanjing), Inc.

Phase 2

Guangzhou, Wuhan, Changsha, Nanjing, Jinan, Linyi, Hangzhou, Beijing

2026-03-17

Recruiting

HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management

NCT07402239Heart Failure

United Innomed(Shanghai) Limited

Not applicable

330

Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai

2026-03-16

By invitation

Development and Implementation of a Breastfeeding Program for Post-Cesarean Section Women Based on the 5A Nursing Model

NCT07913438Breastfeeding Rates

The Third Xiangya Hospital of Central South University

Not applicable

Changsha

2026-03-11

Recruiting

A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children

NCT07402512Respiratory Syncytial Virus Infection

Simcere Pharmaceutical Co., Ltd

Phase 3

498

Xiamen, Changsha, Chengdu, Hangzhou

2026-03-11

Recruiting

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

NCT06951646Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)

DrugsIvonescimab·Docetaxel

Second Xiangya Hospital of Central South University

Phase 2

Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang

2026-03-10

Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

DrugsIdelalisib·Pirtobrutinib

Eli Lilly and Company

Phase 4

150

Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou

2026-03-09

Recruiting

A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

NCT07404202Pan-tumor(NSCLC, GYN Cancers, BTC and UC)

AstraZeneca

Observational

2,100

Beijing, Changsha, Chengdu, Guangzhou, Haerbin, Jinan, Nantong, Shanghai

2026-03-06

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou

2026-03-05

Recruiting

ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy

NCT07453407Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency

Second Affiliated Hospital, Zhejiang University, School of Medicine

Not applicable

1,250

Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Hong Kong, Wuhan, Changsha

2026-03-05

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua

2026-03-05

Recruiting

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

NCT07396584Solid Tumors, Adult

Hutchmed

Phase 1/2

186

Changchun, Changsha, Jinan, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou

2026-03-04

Recruiting

A Study of DXC014 in Patients With Advanced Solid Tumors.

NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors

Hangzhou DAC Biotechnology Co., Ltd.

Phase 1

150

Beijing, Changsha, Nanchang, Qingdao, Hangzhou

2026-03-03

Recruiting

A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma

NCT07436949Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugBBT002

Bambusa Therapeutics

Phase 1/2

Beijing, Guangzhou, Changsha, Nanjing, Jinan, Qingdao, Yantai, Zibo

2026-03-02

Recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers

NCT07474545Healthy Volunteers

DrugsEtomidate·KL0011034

Hunan Kelun Pharmaceutical Co., Ltd.

Phase 1

Changsha

2026-03-02

Recruiting

A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）

NCT07368608Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol

BeBetter Med Inc

Phase 1/2

340

Changsha

2026-03-01

Recruiting

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

NCT07396480Venentoclax, Myeloid Malignancies, Conditioning, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

DrugVenetoclax

First Affiliated Hospital of Zhejiang University

Phase 3

186

Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Hangzhou

2026-03-01

Not yet open

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

NCT07375524Primary Sjögren Syndrome

DrugESG206

Shanghai Escugen Biotechnology Co., Ltd

Phase 2

Beijing, Xiamen, Guilin, Langfang, Changde, Changsha, Zhuzhou, Xuzhou

2026-03-01

Recruiting

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

NCT07441174Solid Tumor Cancer, PDAC

DrugsRNK08954·IN10018

InxMed (Shanghai) Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang

2026-02-28

Recruiting

Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery

NCT07412223Pain, Postoperative, Postoperative Ileus

DrugsTegileridine·Morphine

Xiangya Hospital of Central South University

Phase 4

152

Guangzhou, Changsha

2026-02-24

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing

2026-02-23

Recruiting

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

NCT07361302Acute Ischemic Stroke

DrugTenecteplase

Boehringer Ingelheim

Phase 3

1,325

Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu

2026-02-17

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou

2026-02-16

Recruiting

A Study of Brenipatide in Adult Participants With Schizophrenia

NCT07410507Schizophrenia

DrugBrenipatide

Eli Lilly and Company

Phase 2

450

Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian

2026-02-10

Recruiting

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm

DrugsCasdatifan·PF-08634404·Axitinib·Yervoy

Pfizer

Phase 1/2

224

Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo

2026-02-10

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou

2026-02-10

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

800

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming

2026-02-10

Recruiting

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

NCT07412756Depressive Disorder, Major

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,000

Beijing, Changsha, Chaohu, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou

2026-02-09

Recruiting

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931Osteoarthritis, Overweight or Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan

2026-02-09

Recruiting

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07276958Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis

Eli Lilly and Company

Phase 1

Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan

2026-02-04

Recruiting

Acetaminophen-Mannitol Injection and Postoperative Delirium

NCT07235995Postoperative Delirium

Xiangya Hospital of Central South University

Phase 4

1,092

Changsha

2026-02-02

Recruiting

Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke

NCT07369999Mild Disabling Acute Ischemic Stroke

Xiangya Hospital of Central South University

Phase 3

1,062

Changsha, Chang’an, Cili, Guankou, Huayuan, Lanshan, Leiyang, Pingjiang

2026-02-01

Not yet open

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）

NCT07274137Overweight or Obesity

DrugMDR-001

MindRank AI Ltd

Phase 3

738

Beijing, Changchun, Changde, Changsha, Datong, Dongyang, Ganzhou, Hefei

2026-02

Recruiting

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

NCT07331272Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)

Nanjing Legend Biotech Co.

Phase 1

Bengbu, Guangzhou, Changsha, Xuzhou, Nanchang

2026-01-29

Active, closed

HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

NCT07462923Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

DrugRis-Rez

Hansoh BioMedical R&D Company

Phase 1

Beijing, Fuzhou, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha

2026-01-29

Recruiting

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

NCT07363642Severe Asthma

DrugTezepelumab

AstraZeneca

Phase 3

400

Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou

2026-01-28

Recruiting

Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial

NCT07402525Oral Tongue Squamous Cell Carcinoma

Second Affiliated Hospital, Zhejiang University, School of Medicine

Not applicable

190

Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang

2026-01-26

Active, closed

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

NCT07230860Dermatitis, Atopic

DrugJNJ-95597528

Janssen Research & Development, LLC

Phase 2

189

Beijing, Changsha, Chengde, Chengdu, Guangzhou, Sanmenxia, Wuxi, Xi'an

2026-01-20

Recruiting

The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age

NCT07309562Small for Gestational Age

DrugsInpegsomatropin·Recombinant Human Growth Hormone

Xiamen Amoytop Biotech Co., Ltd.

Phase 3

141

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou

2026-01-20

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan

2026-01-16

Not yet open

Huangjing Yangji Formula Combined With Resistance Training for Sarcopenia

NCT07321535Sarcopenia

Wangjing Hospital, China Academy of Chinese Medical Sciences

Not applicable

106

Beijing, Changsha, Tianjin

2026-01-15

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873Arthritis, Psoriatic

Janssen Research & Development, LLC

Phase 2

157

Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai

2026-01-15

By invitation

AI-based Prediction of Prostate Cancer Metastasis Using Biopsy Pathology

NCT07660276Prostate Cancer Metastatic

Xiangya Hospital of Central South University

Observational

3,000

Changsha

2026-01-08

Recruiting

Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

NCT07441993Marginal Zone Lymphoma

DrugOrelabrutinib

Institute of Hematology & Blood Diseases Hospital, China

Phase 2

Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang

2026-01-05

Recruiting

Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI

NCT07755670Hidradenitis Suppurativa (HS)

Second Xiangya Hospital of Central South University

Observational

Changsha

2026-01-03

Recruiting

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

NCT07303803MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)

DrugsChiglitazar·Vitamin E

Shanghai Jiao Tong University School of Medicine

Phase 2

300

Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Shiyan, Changsha, Changchun

2026-01-01

Not yet open

Stereotactic Aspiration of Brain Stem Hematoma

NCT07300501Brain Stem Hematoma

First Affiliated Hospital of Zhejiang University

Not applicable

300

Hangzhou, Changsha, Guangzhou, Jinan, Shanghai, Shenzhen, Taizhou, Wenzhou

2026-01-01

Not yet open

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

NCT07328919Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

138

Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang

2026-01

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-12-29

Recruiting

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569Hidradenitis Suppurativa

Sanofi

Phase 2

144

Beijing, Changsha, Hangzhou, Shanghai, Wuhan

2025-12-29

Recruiting

Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety

NCT07296497Rosacea

Xiangya Hospital of Central South University

Not applicable

104

Changsha

2025-12-24

Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336Breast Neoplasms, Neoplasm Metastasis

DrugsTersolisib·Exemestane·Anastrozole·Ribociclib

Eli Lilly and Company

Phase 3

800

Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian

2025-12-22

Not yet open

Video Intervention to Reduce Depression-related Stigma Among Adolescents

NCT07282366Depression - Major Depressive Disorder

Jian-Jun Ou

Not applicable

500

Changsha

2025-12-20

Recruiting

GenSci143 in Participants With Advanced Solid Tumors

NCT07252414Advanced Solid Tumors

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

180

Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou

2025-12-20

Recruiting

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

NCT07228247Solid Tumors, Adult

Hutchmed

Phase 1/2

147

Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou

2025-12-16

Recruiting

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis

Sun Yat-sen University

Phase 3

386

Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha

2025-12-16

Recruiting

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

NCT07260708Advanced Cancers

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 1

Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan

2025-12-16

Recruiting

A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

NCT07323173Systemic Lupus Erythematosus

Nanjing Leads Biolabs Co.,Ltd

Phase 1

117

Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan

2025-12-16

Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581Rheumatoid Arthritis

AstraZeneca

Phase 2

320

Beijing, Changchun, Changsha, Guangzhou, Jiujiang, Kunming, Linyi, Nanchong

2025-12-15

Recruiting

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

NCT07307235Type 2 Diabetes

DrugIGlarLixi

Shanghai Zhongshan Hospital

Phase 4

1,316

Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang

2025-12-13

Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

DrugsVepugratinib·Pembrolizumab

Eli Lilly and Company

Phase 3

450

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin

2025-12-12

Recruiting

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267Breast Cancer, Advanced Solid Tumor

DrugBG-75202

BeOne Medicines

Phase 1

Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai

2025-12-11

Recruiting

Direct Visualization ERAT Versus Laparoscopic Appendectomy in Adults With Acute Uncomplicated Appendicitis

NCT07230379Acute Uncomplicated Appendicitis

Changhai Hospital

Not applicable

376

Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang

2025-12-10

Active, closed

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

NCT07211776Thyroid Eye Disease (TED)

DrugVRDN-003

Zai Lab (Shanghai) Co., Ltd.

Phase 3

108

Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou

2025-12-05

Recruiting

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111Neoplasm Malignant

DrugsCalderasib·Cetuximab

Merck Sharp & Dohme LLC

Phase 2

150

Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang

2025-12-04

Recruiting

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

110

Beijing, Guangzhou, Changsha, Hangzhou, Shanghai

2025-12-04

Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer

DrugCretostimogene Grenadenorepvec

Lepu Biopharma Co., Ltd.

Phase 2

Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan

2025-12-04

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou

2025-12-04

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453Plaque Psoriasis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

366

Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai

2025-12-03

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

600

Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou

2025-12-03

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou

2025-12-02

Recruiting

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281Atopic Dermatitis

DrugAbrocitinib

Pfizer

Phase 3

450

Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai

2025-12-02

Recruiting

Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease

NCT07363538Complex Congenital Heart Disease

Central China Fuwai Hospital of Zhengzhou University

Not applicable

738

Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao

2025-12-01

Active, closed

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

NCT07246564Myasthenia Gravis

DrugRozanolixizumab

UCB Biopharma SRL

Phase 4

Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen

2025-12-01

Recruiting

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

NCT07182682Non-Small Cell Lung Cancer

DrugSunvozertinib

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Phase 3

360

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin

2025-12-01

Recruiting

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery

NCT07311369Moderate to Severe Acute Postoperative Pain

DrugHL-1186

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Phase 2

Changsha

2025-12

Recruiting

The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management

NCT06909773Cardiovascular Diseases

AstraZeneca

Not applicable

3,000

Anqing, Beijing, Changsha, Chaohu, Chengdu, Chifeng, Chongqing, Dalian

2025-11-28

Recruiting

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

NCT07362940Non-Small Cell Lung Cancer

DrugsDositinib mesylate·GEN-725

Henan Genuine Biotech Co., Ltd.

Phase 1/2

110

Beijing, Changsha, Jinan, Xiamen, Zhengzhou

2025-11-27

Recruiting

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

NCT07236099Prurigo Nodularis (PN)

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2

135

Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha

2025-11-27

Recruiting

A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease

NCT07640893Von Willebrand Disease (VWD)

DrugSR604

Shanghai RAAS Blood Products Co., Ltd.

Phase 2

Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin

2025-11-26

Recruiting

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

NCT07176650Hepatocellular Carcinoma (HCC)

DrugsYervoy·Opdivo

Shanghai Henlius Biotech

Phase 1

246

Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou

2025-11-25

Recruiting

A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

NCT07286175Bipolar Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 2

400

Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen

2025-11-24

Active, closed

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

NCT07162883Carcinoma, Non-Small-Cell Lung

DrugsKeytruda·Pembrolizumab

Qilu Pharmaceutical Co., Ltd.

Phase 3

146

Bengbu, Beijing, Chongqing, Lanzhou, Haikou, Zhengzhou, Changsha, Nanjing

2025-11-21

Recruiting

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

NCT07650084Refractory Chronic Cough

DrugCamlipixant

GlaxoSmithKline

Phase 3

Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou

2025-11-21

Recruiting

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

NCT07328841Nasopharyngeal Carcinoma (NPC)

Ming-Yuan Chen

Phase 3

456

Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong

2025-11-18

Recruiting

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

NCT07095868Selected Types of Solid Tumor

Everest Medicines (Beijing) Co., Ltd.

Phase 1/2

Changsha, Nanjing, Shanghai

2025-11-17

Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803Atopic Dermatitis

Sanofi

Observational

1,000

Beijing, Shenzhen, Changsha, Xi’an, Chengdu, Hangzhou, Ningbo, Chongqing

2025-11-17

Recruiting

GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer

DrugGKL-006

Beijing Gene Key Life Technology Co., Ltd

Phase 2

Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou

2025-11-14

Recruiting

Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors

NCT06144671Advanced Solid Tumors

DrugsGT201·Aldesleukin·Tuoyi

Grit Biotechnology

Phase 1/2

Guangzhou, Nanning, Changsha, Shanghai, Chengdu

2025-11-01

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2025-10-31

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou

2025-10-30

Recruiting

Genetic Risk Score of Type 1 Diabetes Mellitus for Progression to Insulin in Diabetic Patients Lack of Predictive Value: a Multicenter Nested Case-control Study

NCT07621445Diabetes Mellitus, Diabetes Mellitus, Type 1

Second Xiangya Hospital of Central South University

Observational

2,950

Changsha

2025-10-27

Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou

2025-10-24

Recruiting

Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases

NCT07469267Breast Cancer, Radiotherapy

Fudan University

Not applicable

1,608

Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan

2025-10-24

Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126Non-small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

686

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin

2025-10-24

Recruiting

TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage

NCT07187687Intracerebral Hemorrhage

Xuanwu Hospital, Beijing

Not applicable

750

Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng

2025-10-24

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan

2025-10-22

Recruiting

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

NCT07272434Respiratory Syncytial Virus (RSV)

DrugRecombinant Respiratory Syncytial Virus Vaccine

MAXVAX Biotechnology Limited Liability Company

Phase 3

25,000

Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu

2025-10-22

Recruiting

Neuroprotection Bundles For Comatose Survivors Following Cardiac Arrest

NCT06992843Cardiac Arrest, Post-cardiac Arrest Care

Xiangya Hospital of Central South University

Not applicable

1,008

Changsha

2025-10-22

Recruiting

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

1,196

Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing

2025-10-20

Recruiting

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

NCT07111546Advanced Solid Tumour

DrugsLBL-024·Gemcitabine·Bevacizumab·Cisplatin

Nanjing Leads Biolabs Co.,Ltd

Phase 2

140

Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha

2025-10-20

Active, closed

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

NCT07169331Waldenström's Macroglobulinemia

DrugZanubrutinib

BeiGene

Phase 4

Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou

2025-10-17

Recruiting

A Study of Brenipatide in Participants With Alcohol Use Disorder

NCT07219953Alcohol Use Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,100

Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei

2025-10-16

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang

2025-10-15

Recruiting

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

NCT07219966Alcohol Use Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,100

Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou

2025-10-15

Recruiting

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913Mania, Bipolar Disorder

DrugKarXT

Bristol-Myers Squibb

Phase 3

424

Beijing, Guangzhou, Baoding, Shijiazhuang, Changsha, Nanjing, Xi'an, Chengdu

2025-10-08

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou

2025-10-03

Recruiting

Mobile Health and Wearable Devices for Diabetes Complication Management

NCT07129148Diabetes Mellitus Type 2, Diabetes Mellitus Complications

Second Xiangya Hospital of Central South University

Not applicable

6,000

Changsha

2025-10-01

Active, closed

Microfocused Ultrasound for Facial Pigmentary Diseases and Rosacea

NCT07667972Melasma, Rosacea, Periorbital Hyperpigmentation, Melanosis

Xiangya Hospital of Central South University

Not applicable

200

Changsha

2025-10-01

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Changsha, Chengdu, Wuhan

2025-10-01

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

980

Xiamen, Guangzhou, Huizhou, Shenzhen, Wuhan, Changsha, Nanjing, Wuxi

2025-10-01

Not yet open

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

NCT06364904Bladder Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

210

Guangzhou, Wuhan, Changsha

2025-10

Not yet open

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

NCT07163481Stage IV (Metastatic) Breast Cancer

DrugsAnastrozole, Exemestane·Sacituzumab Govitecan·Fulvestrant

Hunan Cancer Hospital

Phase 1

Changsha

2025-10

Not yet open

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

NCT07135141Severe Obesity

Beijing Friendship Hospital

Not applicable

256

Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai

2025-09-30

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong

2025-09-30

Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275Primary Membranous Nephropathy

DrugsPovetacicept·Tacrolimus

Vertex Pharmaceuticals Incorporated

Phase 2/3

176

Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan

2025-09-30

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an

2025-09-28

Recruiting

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

NCT07083154Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes

DrugMazdutide

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3

420

Changsha, Changzhou, Nanjing, Dalian, Shanghai

2025-09-27

Active, closed

Study of CM355 in Patients With Systemic Lupus Erythematosus

NCT07104344Systemic Lupus Erythematosus

DrugCM355

Second Xiangya Hospital of Central South University

Not applicable

Changsha

2025-09-25

Recruiting

Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors

NCT07186452Advanced Solid Tumors

DrugsRis-Rez·Itraconazole

Hansoh BioMedical R&D Company

Phase 1

Changsha

2025-09-23

Recruiting

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugsBirelentinib·Venetoclax

Dizal Pharmaceuticals

Phase 2

Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou

2025-09-22

Recruiting

A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis

DrugDelamanid

WestVac Biopharma Co., Ltd.

Phase 2

Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai

2025-09-19

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian

2025-09-17

Recruiting

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin

2025-09-16

Recruiting

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

NCT07029828Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

140

Beijing, Guangzhou, Changsha, Shanghai, Chengdu, Hangzhou

2025-09-10

Recruiting

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT07174908Non-Small Cell Lung Cancer

DrugsD-1553·IN10018

InxMed (Shanghai) Co., Ltd.

Phase 3

400

Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang

2025-09-10

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk

DrugZilebesiran

Alnylam Pharmaceuticals

Phase 3

11,000

Beijing, Binhai, Changchun, Changsha, Chengdu, Chenzhou, Chifeng, Chongqing

2025-09-06

Recruiting

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

NCT07215663Systemic Lupus Erythematosus (SLE)

DrugCizutamig

Candid Therapeutics

Phase 1

Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai

2025-09-04

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing

2025-09-02

Not yet open

Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis

NCT07131150Idiopathic Pulmonary Fibrosis (IPF)

Ruijin Hospital

Phase 2

Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing

2025-08-31

Recruiting

A Study of SKB518 in Patients With Lung Cancer

NCT07019675Lung Carcinoma

DrugsSKB518·Tislelizumab·Carboplatin

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2

192

Shenzhen, Nanning, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanchang, Jinan

2025-08-29

Recruiting

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

NCT07138755NSCLC, Sintilimab, Adaptive Radiotherapy

The Third Xiangya Hospital of Central South University

Phase 2

Changsha, Hengyang, Jishou

2025-08-29

Recruiting

Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers

NCT07207291Bacterial Infections, Urinary Tract Infections, Intra-Abdominal Infections, Respiratory Tract Infections

Joincare Pharmaceutical Group Industry Co., Ltd

Phase 1

Changsha

2025-08-22

Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer

Pfizer

Phase 1

540

Changsha

2025-08-20

Recruiting

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

NCT07059650Diffuse Large B-Cell Lymphoma

DrugsR-GemOx·Birelentinib·R-Chop

Dizal Pharmaceuticals

Phase 1/2

150

Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan

2025-08-19

Recruiting

Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2

NCT07097818Type 1 Diabetes

Second Xiangya Hospital of Central South University

Not applicable

400

Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang

2025-08-18

Recruiting

Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia

NCT06973356Immune Thrombocytopenia (ITP)

Anhui Provincial Hospital

Not applicable

Changsha

2025-08-16

Not yet open

Blended Unified Protocol for Chinese Adolescents With Non-Suicidal Self-Injury: A Randomized Controlled Trial

NCT07110181Non-suicidal Self-injury (NSSI)

Jian-Jun Ou

Not applicable

Changsha

2025-08-15

Recruiting

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

NCT07125755Squamous Cell Cancer of Head and Neck (SCCHN)

DrugCisplatin

Sun Yat-sen University

Phase 3

386

Guangzhou, Guilin, Sanya, Changsha, Nanjing

2025-08-15

By invitation

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

NCT07376629TNBC

DrugsHB0025·Nab-paclitaxel

Huabo Biopharm Co., Ltd.

Phase 2

Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin

2025-08-14

Active, closed

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

NCT07128121Respiratory Syncytial Virus (RSV) Infection

Shenzhen Shenxin Biotechnology Co., Ltd

Phase 2

500

Changsha

2025-08-13

Recruiting

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT07239947Atopic Dermatitis

DrugBBT001

Bambusa Therapeutics

Phase 1

Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang

2025-08-09

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei

2025-08-07

Active, closed

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

212

Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan

2025-08-07

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot

2025-08-06

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua

2025-08-06

Recruiting

Interventional Left Ventricular Assist System for PCI in CHIP Patients

NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices

Suzhou Hengruihongyuan Medical Technology Co. LTD

Not applicable

286

Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang

2025-08-06

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)

Shanghai Henlius Biotech

Phase 2

Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing

2025-08-05

Recruiting

A Study of YL202 in Patients With Advanced Solid Tumors

NCT07202364Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors

DrugYL202

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2

100

Changsha

2025-08-04

Recruiting

Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease

NCT07123207Mild to Severe Crohns Disease

The Third Xiangya Hospital of Central South University

Not applicable

Changsha

2025-08-04

Recruiting

Real World Evidence Study of SYN023 in Children Exposed to Rabies

NCT07327307Rabies Post-exposure Prophylaxis

Synermore Biologics (Suzhou) Co., Ltd.

Observational

232

Beijing, Shenzhen, Changsha, Hengyang, Nanchang

2025-08-02

Recruiting

The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis

NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

250

Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan

2025-08-01

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou

2025-08-01

Recruiting

Assessment of DOT Spectacles in Chinese Children Extension

NCT07008001Juvenile Myopia, Myopia

SightGlass Vision, Inc.

Not applicable

175

Changsha, Chengdu, Guangzhou, Shanghai, Tianjin

2025-08-01

Not yet open

Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions

NCT07023575Interstitial Lung Abnormalities

China-Japan Friendship Hospital

Observational

100,000

Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang

2025-08-01

Not yet open

Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

NCT07133815Homozygous Familial Hypercholesterolemia

DrugSHR-1918

Beijing Suncadia Pharmaceuticals Co., Ltd

Phase 2

Changsha

2025-08

Not yet open

the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery

NCT06530563Acute Pain, Opioid Analgesic Adverse Reaction

DrugsSufentanil Citrate·Oliceridine·Sufentanil

Xiangya Hospital of Central South University

Phase 4

606

Changsha

2025-08

Not yet open

A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112

DrugsPenpulimab·Ivonescimab

Yang Fan, MD

Phase 2

164

Beijing, Changsha, Shanghai, Xi’an, Hangzhou

2025-07-31

Active, closed

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

208

Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou

2025-07-31

Recruiting

A Clinical Study of GO306 in Patients With Advanced Solid Tumors

NCT07128914Solid Tumor Malignancies

GeneSail Biotech (Shanghai) Co., Ltd.

Phase 1

Hefei, Fuzhou, Shenzhen, Zhengzhou, Changsha, Shanghai

2025-07-31

Recruiting

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

NCT07061535Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer

DrugsTafolecimab·Etoposide·Sintilimab·Docetaxel

Second Affiliated Hospital, Zhejiang University, School of Medicine

Phase 2

Changsha, Jinan, Hangzhou

2025-07-30

Recruiting

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

NCT07079475Non-Small Cell Lung Cancer

DrugsDZD6008·Sunvozertinib·Osimertinib

Dizal Pharmaceuticals

Phase 1/2

220

Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai

2025-07-30

Recruiting

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)

DrugsHDM2005·Rituximab Biosimilar·Doxorubicin·Prednisone

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha

2025-07-30

Recruiting

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519Ulcerative Colitis

DrugRisankizumab

AbbVie

Phase 3

120

Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou

2025-07-28

Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502Follicular Lymphoma

DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine

Celgene

Phase 3

400

Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou

2025-07-28

Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer

DrugMRG007

ArriVent BioPharma, Inc.

Phase 1

572

Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong

2025-07-25

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

Beijing, Quanzhou, Luoyang, Xinxiang, Zhengzhou, Changsha, Shaoyang, Nanjing

2025-07-24

Recruiting

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT06807268Eczema

DrugAbrocitinib

Pfizer

Phase 3

150

Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou

2025-07-24

Recruiting

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

NCT07024173Locally Advanced Breast Cancer, Metastatic Breast Cancer

DrugsHRS-8080·Exemestane·Anastrozole·Everolimus

Shandong Suncadia Medicine Co., Ltd.

Phase 3

240

Guangzhou, Changsha

2025-07-23

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian

2025-07-22

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

NCT07005713Chronic Spontaneous Urticaria

DrugTacabrutideg

BeOne Medicines

Phase 1

Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou

2025-07-19

Recruiting

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273Bipolar Disorder Type I With Mania

DrugsValproate·Lamotrigine·Lithium·KarXT

Bristol-Myers Squibb

Phase 3

450

Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin

2025-07-18

Recruiting

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

NCT06953089Solid Tumors

DrugsDB-1305/BNT325·Pumitamig

DualityBio Inc.

Phase 2

750

Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou

2025-07-18

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Beijing, Changping, Xiamen, Guangdong, Guangzhou, Shenzhen, Changsha, Baotou

2025-07-15

Recruiting

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

NCT07043751Advanced Malignant Tumors

DrugTQB6411

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

216

Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha

2025-07-15

By invitation

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study

NCT06882876Hepatocellular Carcinoma (HCC)

Xiangya Hospital of Central South University

Phase 1

Changsha

2025-07-10

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732Alzheimer Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai

2025-07-10

Recruiting

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

NCT06953323Advanced Solid Tumor

DrugsWJB001·Niraparib·Paclitaxel·Bevacizumab

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou

2025-07-10

Recruiting

Manual Thrombus Aspiration During PCI in STEMI With Angiographically Evident Thrombus

NCT06654453ST-segment Elevation Myocardial Infarction

Shenghua Zhou

Not applicable

3,500

Changsha

2025-07-09

Recruiting

Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy

NCT07823049Pancreatic Cancer

DrugXNW28012

Evopoint Biosciences Inc.

Phase 3

226

Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang

2025-07-08

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 4

Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot

2025-07-04

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou

2025-07-02

Recruiting

Rectal NSAIDs With/Without PD Stent for PEP Prevention

NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement

DrugNSAIDs

Air Force Military Medical University, China

Not applicable

1,278

Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an

2025-07-01

Recruiting

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients

NCT07045142Schizophrenia

DrugsAtorvastatin·Metformin

Central South University

Phase 3

400

Zhumadian, Changsha, Yueyang, Dali, Xiangshan

2025-07-01

Not yet open

BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma

NCT07008053Marginal Zone Lymphomas

Tianjin Medical University Cancer Institute and Hospital

Phase 2

Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin

2025-07

Not yet open

A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

NCT07038460Resectable Non-small Cell Lung Cancer

DrugsLimertinib·Osimertinib·Sintilimab

Wen-zhao ZHONG

Phase 2

134

Guangzhou, Changsha, Hangzhou

2025-07

Recruiting

A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

NCT07071090Solid Tumor Malignancies

Heronova Pharmaceuticals

Phase 1

Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou

2025-06-30

Recruiting

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

NCT06962865Non-Small Cell Lung Cancer

DrugsFurmonertinib Mesilate·Furmonertinib

RemeGen Co., Ltd.

Phase 2

Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou

2025-06-30

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-06-27

Recruiting

Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition

NCT07121504Type 2 Diabetes

Second Xiangya Hospital of Central South University

Not applicable

Changsha

2025-06-26

Recruiting

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial

NCT07103382Obesity

Second Xiangya Hospital of Central South University

Not applicable

Changsha

2025-06-26

Active, closed

Hyperkalemia Quality Improvement Program (HK-QIP) Study

NCT06884267Hyperkalemia

AstraZeneca

Not applicable

1,000

Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang

2025-06-25

Recruiting

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

NCT07070479Recurrent or Metastatic Nasopharyngeal Carcinoma

DrugsMitoxantrone Hydrochloride Liposome·Venetocalx·Irinotecan liposome·Nimotuzumab

Ming-Yuan Chen

Phase 2

208

Guangzhou, Zhongshan, Zhuhai, Changsha

2025-06-24

Recruiting

Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer

NCT06926140Lung Cancers

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Not applicable

240

Hefei, Beijing, Changsha

2025-06-21

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

981

Haikou, Changsha, Chengdu, Beijing, Changchun, Chongqing, Dongguan, Fuyang

2025-06-20

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an

2025-06-19

Recruiting

The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction

NCT06995118Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Du Zhenggui

Not applicable

337

Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang

2025-06-17

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha

2025-06-17

Recruiting

IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study

NCT07034664Crohn's Disease, Guselkumab, Intestinal Ultrasound, Predictor

The Third Xiangya Hospital of Central South University

Observational

Changsha

2025-06-16

Recruiting

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis

Alebund Pharmaceuticals

Phase 3

264

Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi

2025-06-13

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features

DrugKarXT

Bristol-Myers Squibb

Phase 3

274

Beijing, Wuhan, Changsha, Jining Shi, Tianjin

2025-06-13

Active, closed

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235Hidradenitis Suppurativa

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

149

Guangzhou, Changsha, Changchun, Shanghai, Ürümqi, Hangzhou

2025-06-09

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei

2025-06-09

Active, closed

A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors

NCT06993116Advanced Solid Tumor

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 1

Fuzhou, Changsha

2025-06-09

Active, closed

A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases

NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN

DrugSGB-9768

Suzhou Sanegene Bio Inc.

Phase 2

Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan

2025-06-06

Recruiting

First-in-Human Single and Multiple Dose of KLA578-1 for Injection

NCT07143318Healthy Volunteers

Hunan Kelun Pharmaceutical Co., Ltd.

Phase 1

Changsha

2025-06-05

Recruiting

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT07038343Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers

Avenzo Therapeutics, Inc.

Phase 1/2

480

Beijing, Chongqing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan

2025-06-04

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

Anqing, Anyang, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha

2025-06-04

Recruiting

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

NCT06958536Crohn's Disease

DrugBrivekimig

Sanofi

Phase 2

Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang

2025-06-03

Recruiting

Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer

NCT07063901Esophagus Cancer

Central South University

Observational

200

Changsha

2025-06-01

Recruiting

A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on the Natural Pregnancy Outcomes in Patients With Non-recurrent Spontaneous Abortion

NCT07039097Infertility and Miscarriage

The Third Xiangya Hospital of Central South University

Not applicable

418

Changsha

2025-06-01

Recruiting

A Multicenter, Prospective, Randomized Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on IVF-ET Outcomes in Infertile Patients With Non-recurrent Miscarriage

NCT07611656Infertility and Miscarriage

The Third Xiangya Hospital of Central South University

Not applicable

236

Changsha

2025-06-01

Recruiting

Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces

NCT07066813Lung Cancer Associated With Cystic Airspaces

Central South University

Observational

500

Changsha

2025-06-01

Recruiting

Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study

NCT07093294Crohn Disease (CD), Vedolizumab, Intestinal Ultrasound, Predictor

The Third Xiangya Hospital of Central South University

Observational

Changsha

2025-06-01

Recruiting

Indomethacin vs Diclofenac for Preventing PEP

NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin

DrugsIndomethacin·Diclofenac

Air Force Military Medical University, China

Not applicable

4,050

Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City

2025-06-01

Recruiting

Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease

NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis

Second Affiliated Hospital, Zhejiang University, School of Medicine

Observational

10,000

Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, Ürümqi

2025-06-01

Recruiting

Xiangya Cardiopulmonary Health and Disease Cohort

NCT06972784Respiratory Function Tests，Heart Function Tests, Cardiopulmonary Function

Xiangya Hospital of Central South University

Observational

30,000

Changsha

2025-06-01

Recruiting

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

NCT06954467Hepatocellular Carcinoma

DrugsJS007·JS207

Shanghai Junshi Bioscience Co., Ltd.

Phase 2

Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai

2025-05-29

Recruiting

Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury

NCT06947135Acute Myocardial Infarction

DrugMorphine

The Second Hospital of Anhui Medical University

Not applicable

166

Hefei, Changsha

2025-05-29

Recruiting

Evaluation of GM101 Injection in Patients With Parkinson's Disease

NCT07100171Parkinson's Disease

Genemagic Biosciences Co., Ltd

Early Phase 1

Changsha

2025-05-29

Recruiting

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

4,200

Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian

2025-05-20

Recruiting

A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors

NCT07050459Locally Advanced Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

220

Beijing, Haerbin, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Chengdu

2025-05-20

Recruiting

Establishment of Diagnosis and Classification System for Lung Interstitial and Airway Diseases (LIAD)

NCT06987266Interstitial Lung Diseases (ILD), Airway Disease

Xiangya Hospital of Central South University

Observational

900

Changsha

2025-05-20

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai

2025-05-16

Recruiting

A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data

NCT07126821Brain (Nervous System) Cancers, Brain Arterial Disease, Neuro-Degenerative Disease, Brain Tumors

Xiangya Hospital of Central South University

Observational

100,000

Changsha

2025-05-15

Recruiting

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

NCT06957886HER2-low Breast Cancer

DrugsT-Bren·Albumin paclitaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3

566

Guangzhou, Changsha

2025-05-15

Recruiting

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

NCT06926283Prostate Cancer, Other Solid Tumors, Ewing Sarcoma

Hangzhou DAC Biotechnology Co., Ltd.

Phase 1

110

Changsha, Hangzhou, Beijing

2025-05-15

Active, closed

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

NCT06890533Pain

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Phase 3

560

Cangzhou, Changde, Changsha, Chengdu, Chongqing, Ch’ang-ch’un, Dalian, Deyang

2025-05-14

Recruiting

A Study of ZL-1310 in Participants With Selected Solid Tumors

NCT06885281Solid Tumors

DrugZL-1310

Zai Lab (Shanghai) Co., Ltd.

Phase 1/2

166

Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai

2025-05-12

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Guangzhou, Changsha, Shanghai, Kunming

2025-05-12

Active, closed

Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

NCT06937476Major Depressive Disorder (MDD), Rumination

DrugsAripiprazole·Escitalopram

Central South University

Not applicable

108

Changsha

2025-05-08

Recruiting

Crisugabalin for Radiotherapy-Related Neuropathic Pain

NCT06766916Neuropathic Pain

DrugsCrisugabalin·Pregabalin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

172

Fuzhou, Guangzhou, Zhongshan, Nanning, Zhengzhou, Changsha

2025-05-07

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou

2025-05-06

Recruiting

Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads

NCT06947356Hepatitis B

Guangzhou 8th People's Hospital

Not applicable

210

Guangzhou, Shenzhen, Shijiazhuang, Changsha, Wenzhou, Beijing

2025-05-03

Recruiting

Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces

NCT07820423Lung Cancer Associated With Cystic Airspaces

Central South University

Observational

600

Changsha

2025-05-01

Not yet open

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

NCT06828757Non Small Cell Lung Cancer

Hunan Province Tumor Hospital

Phase 3

Changsha

2025-05-01

Recruiting

Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer

NCT07098026Gastric Cancer, Adenocarcinoma

Hunan Cancer Hospital

Not applicable

286

Changsha

2025-05-01

Recruiting

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

NCT06862869Carcinoma, Non-Small-Cell Lung

DrugAlectinib

Hoffmann-La Roche

Observational

800

Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, Ürümqi, Beijing, Changsha, Changzhou

2025-04-30

Recruiting

Study on the Aortic Arch Single Branch Stent Graft System

NCT06915545Aortic Dissection

Lifetech Scientific (Shenzhen) Co., Ltd.

Not applicable

135

Changsha

2025-04-30

Recruiting

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

NCT06937944Moderate to Severe Glabellar Lines

DrugsOnabotulinumtoxinA·Botox

JHM BioPharma (Tonghua) Co. , Ltd.

Phase 3

669

Beijing, Chongqing, Guangzhou, Shijiazhuang, Changsha, Xuzhou, Shanghai, Xianyang

2025-04-30

Recruiting

Blended Unified Protocol in Chinese Adolescents With Non-Suicidal Self-Injury

NCT06858540Non-suicidal Self-injury (NSSI)

Jian-Jun Ou

Not applicable

Changsha

2025-04-29

Recruiting

Skin Type Determination Using Image Artificial Intelligence

NCT07765303Skin Ageing, Skin

Region Skane

Observational

1,500

Changsha

2025-04-28

Recruiting

Clinical Study on the Effectiveness and Safety of Succinylated Gelatin Electrolyte Sodium Acetate Injection

NCT06977750Acute Normovolemic Hemodilution

Nanjing Chia-tai Tianqing Pharmaceutical

Not applicable

104

Changsha

2025-04-27

Recruiting

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06974812Unresectable Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2

250

Fuzhou, Changsha, Shanghai

2025-04-18

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou

2025-04-10

Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217Lennox Gastaut Syndrome

DrugClemizole HCl

Epygenix

Phase 3

260

Changsha, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang

2025-04-09

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan

2025-04-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen

2025-04-09

Recruiting

The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

NCT06946901Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Metastatic Pancreatic Cancer

Shanghai Zhongshan Hospital

Phase 2

Changsha, Shanghai

2025-04-03

Recruiting

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

NCT06839066Nasopharyngeal Carcinoma (NPC)

DrugsHLX43 3·HLX43 2·HLX43 1

Shanghai Henlius Biotech

Phase 2

Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha

2025-04-02

Recruiting

Establishment of a Classification System and Postoperative Risk Warning Model for Patients Undergoing Bariatric Metabolic Surgery for Severe Obesity

NCT07093502Obesity, Bariatric Surgery, Bariatric Surgery (Sleeve Gastrectomy )

The Third Xiangya Hospital of Central South University

Observational

2,000

Changsha

2025-04-01

Recruiting

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

NCT06825546Advanced Pancreatic Ductal Adenocarcinoma

DrugIcaritin

Sir Run Run Shaw Hospital

Phase 2

Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou, Wenzhou

2025-04-01

Recruiting

A Large-scale, Prospective Cohort Study Was Conducted to Explore the Association Between Environmental Exposure and Behavioral Factors and Infertility (the Success Rate of Assisted Reproductive Technology)

NCT07641387Infertility, Infertility Assisted Reproductive Technology, Infertility (IVF Patients)

The Third Xiangya Hospital of Central South University

Not applicable

5,000

Changsha

2025-04-01

By invitation

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

300

Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan

2025-04-01

Recruiting

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945Alopecia Areata

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 3

674

Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming

2025-04-01

Not yet open

A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

NCT06922929Prostate Cancer Recurrent

DrugINR101

Yunhe Pharmaceutical (Tianjin) Co., Ltd

Phase 3

110

Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou

2025-04

Not yet open

Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

NCT06922903Prostate Cancer

DrugINR101

Yunhe Pharmaceutical (Tianjin) Co., Ltd

Phase 3

240

Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou

2025-04

Recruiting

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

NCT06833983Hemophilia A

DrugGS1191-0445

Gritgen Therapeutics Co., Ltd.

Phase 3

Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha

2025-03-31

Recruiting

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic

DrugsOlverembatinib·Blinatumomab·Daunorubicin·Cytarabine

Institute of Hematology & Blood Diseases Hospital, China

Phase 3

150

Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin

2025-03-28

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou

2025-03-27

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou

2025-03-27

Recruiting

Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical Trial

NCT06932328Acute Pharyngitis

Jianmin Pharmaceutical Group Co., LTD.

Phase 2

216

Harbin, Changsha, Changchun, Jinan, Luzhou, Tianjin, Wenzhou

2025-03-26

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

Beijing, Chongqing, Changsha, Changchun, Chengdu

2025-03-25

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou

2025-03-19

Recruiting

Interleukin-2 for Refractory Chronic Spontaneous Urticaria

NCT06924762Chronic Spontaneous Uriticaria

Second Xiangya Hospital of Central South University

Phase 2/3

124

Changsha

2025-03-19

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-03-18

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2025-03-17

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng

2025-03-14

Not yet open

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer

NCT06866977Pancreatic Cancer

DrugVRT106

Xiangya Hospital of Central South University

Phase 1/2

Changsha

2025-03-12

Recruiting

Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression

NCT06938373Breast Neoplasms

Xiangya Hospital of Central South University

Observational

1,000

Changsha

2025-03-11

Recruiting

Newly-diagnosed Pediatric T-cell ALL Protocol

NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

DrugsAsparaginase·Homoharringtonine·Dasatinib·Daunorubicin

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3

610

Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha

2025-03-11

Active, closed

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR

DrugALXN2030

Alexion Pharmaceuticals, Inc.

Phase 2

Changsha, Guangzhou, Nanning, Shanghai, Wuhan, Xi'an

2025-03-07

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang

2025-03-06

By invitation

Continuous Glucose Monitoring System: Accuracy and Prognostic Value in Critically Ill Patients

NCT07108179Critically Ill Patients

Sinocare

Observational

120

Changsha

2025-03-04

Recruiting

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)

DrugsAsparaginase·Blinatumomab·Daunorubicin·Cytarabine

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3

3,000

Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha

2025-03-03

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan

2025-03-03

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou

2025-03-01

Recruiting

Investigating the Association Between Diagnostic and Therapeutic Management Models and Prognosis of Intrauterine Adhesions Based on a Large-Scale Prospective Cohort Study

NCT07421908Intrauterine Adhesion

The Third Xiangya Hospital of Central South University

Not applicable

5,000

Changsha

2025-03-01

Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)

NextCure, Inc.

Phase 1

738

Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai

2025-02-26

Active, closed

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323Small Cell Lung Cancer (SCLC)

DrugTarlatamab

Amgen

Phase 2

252

Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin

2025-02-26

Recruiting

Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

NCT06840704Non Small Cell Lung Cancer, Small Cell Lung Cancer

Hunan Cancer Hospital

Phase 3

121

Changsha, Chenzhou, Hengyang, Yueyang

2025-02-25

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha

2025-02-25

Recruiting

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

NCT06741644Advanced Solid Tumors

DrugsLeucovorin·Irinotecan·Adrucil·Etoposide

CStone Pharmaceuticals

Phase 1/2

800

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin

2025-02-24

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi

2025-02-21

Recruiting

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

NCT06809764Non-small Cell Lung Cancer

Daiichi Sankyo

Observational

150

Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei

2025-02-21

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

DrugsAWT020·Taxol·Pemetrexed·Capecitabine

Shanghai Junshi Bioscience Co., Ltd.

Phase 1

214

Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun

2025-02-21

Recruiting

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

NCT06889688Breast Cancer Stage IV, Triple -Negative Breast Cancer

DrugsEribulin·Apatinib·Camrelizumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

246

Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai

2025-02-21

Active, closed

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

NCT06702618Breast Cancer

DrugsTQB3616·Fulvestrant

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

Bengbu, Jiangmen, Xingtai, Harbin, Luohe, Changsha, Nanjing, Nantong

2025-02-20

Recruiting

Modified Tumor-free Techniques Operation to Cervical Cancer

NCT06836869Cervical Cancer Stage IB2

Peking Union Medical College Hospital

Not applicable

524

Lanzhou, Guangzhou, Cangzhou, Shijiazhuang, Changsha, Changchun, Shanghai, Xianyang

2025-02-20

Active, closed

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin

NCT06767761Diabetes

DrugDegludec

Gan & Lee Pharmaceuticals.

Phase 3

580

Changsha

2025-02-18

Recruiting

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

NCT06864624NSCLC

DrugSunvozertinib

Tang-Du Hospital

Phase 2

Changsha, Yinchuan, Xi'an

2025-02-18

Active, closed

Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

NCT06712888Nasopharyngeal Carcinoma (NPC)

Sun Yat-sen University

Phase 3

466

Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu

2025-02-17

Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819Advanced Solid Tumors, HER2 Mutation

DrugSevabertinib

Bayer

Phase 2

111

Beijing, Changsha, Shanghai, Hangzhou

2025-02-13

Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 3

256

Hefei, Guangzhou, Changsha, Chifeng, Suzhou, Beijing, Chengdu, Fujian

2025-02-10

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

NCT06624670Pyoderma Gangrenosum

DrugsSpesolimab·Prednisolone·Prednisone

LEO Pharma

Phase 3

Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen

2025-02-05

Recruiting

The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System

NCT07136025Asthma

Beijing Chao Yang Hospital

Not applicable

200

Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou

2025-02-01

Recruiting

Chronic Airway Disease and Multimorbidity Cohort

NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis

China-Japan Friendship Hospital

Observational

2,000

Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai

2025-02-01

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

588

Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu

2025-01-31

Active, closed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

DrugM9140

EMD Serono Research & Development Institute, Inc.

Phase 1/2

184

Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou

2025-01-29

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

NCT06609005Advanced Metastatic Castration Resistant Prostate Cancer

Shenzhen Ionova Life Sciences Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang

2025-01-23

Active, closed

Changes in Fat and Muscle Tissue Function and Their Impact on Metabolic Health After Bariatric Surgery

NCT07035483Obesity and Obesity-related Medical Conditions, Sarcopenic Obesity, Adipose Tissue, Abdominal

Shaihong Zhu

Observational

120

Changsha

2025-01-18

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-china/city/changsha

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 12 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,159 of those studies with a site in Changsha.

How many clinical trials are recruiting in Changsha?

662 of the 1,159 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:17 UTC sync. A further 112 have not yet opened recruitment, 361 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changsha), 1,159 studies
Phase	Studies	Recruiting	Share
Phase 3	440	205	38%
Phase 2	193	104	16.7%
Observational	139	96	12%
Not applicable	133	85	11.5%
Phase 1	107	73	9.2%
Phase 1/2	92	67	7.9%
Phase 2/3	30	20	2.6%
Phase 4	23	11	2%
Early Phase 1	2	1	0.2%

Most active sponsors

Lead sponsors with the most studies (Changsha)
Lead sponsor	Studies	Recruiting
AstraZeneca	139	71
Xiangya Hospital of Central South University	50	30
Eli Lilly and Company	37	21
Second Xiangya Hospital of Central South University	37	28
Janssen Research & Development, LLC	31	10
The Third Xiangya Hospital of Central South University	26	18
Hoffmann-La Roche	24	6
Hunan Province Tumor Hospital	23	17
Pfizer	22	11
Central South University	21	14

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.